Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SERA
SERA logo

SERA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Sera Prognostics Inc (SERA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.750
1 Day change
-7.41%
52 Week Range
4.090
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Sera Prognostics Inc (SERA) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock is in a bearish technical trend, insiders are selling heavily, and there is no recent news or significant financial performance data to support a strong positive outlook. While analysts have a positive long-term price target of $6, the current price trend and lack of immediate catalysts suggest holding off on investment for now.

Technical Analysis

The stock is in a bearish trend with MACD showing negative expansion (-0.0374), RSI at 25.95 (neutral zone), and moving averages indicating a downward momentum (SMA_200 > SMA_20 > SMA_5). Key support is at 1.794, and resistance is at 2.015.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
12
Buy
5

Positive Catalysts

  • Craig-Hallum initiated coverage with a Buy rating and a $6 price target, citing the potential of Sera's proprietary PreTRM test and a large addressable market. The PRIME study could act as a future catalyst for adoption and coverage.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 2019.12% increase in selling activity over the last month. There are no significant hedge fund trading trends, and no recent news or congress trading data to support positive sentiment. The stock is also projected to decline slightly in the short term based on historical patterns.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Craig-Hallum has initiated coverage with a Buy rating and a $6 price target, highlighting the company's innovative product and market potential.

Wall Street analysts forecast SERA stock price to rise
3 Analyst Rating
Wall Street analysts forecast SERA stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.890
sliders
Low
5
Averages
5
High
5
Current: 1.890
sliders
Low
5
Averages
5
High
5
Craig-Hallum
Buy
initiated
$6
AI Analysis
2026-06-04
Reason
Craig-Hallum
Price Target
$6
AI Analysis
2026-06-04
initiated
Buy
Reason
As previously reported, Craig-Hallum initiated coverage of Sera Prognostics with a Buy rating and $6 price target. The firm notes Sera has a proprietary test to identify asymptomatic women at risk of premature delivery - a $2B-plus TAM. Sera's test, PreTRM, is "magnitudes better" than the current approach, Craig-Hallum argues, adding that the landmark PRIME study published in January should be a catalyst for both adoption and coverage over time. The firm believes that coverage decisions could come more quickly than the market anticipates, which should be a catalyst for the shares.
Craig-Hallum
NULL
to
Buy
initiated
$6
2026-06-04
Reason
Craig-Hallum
Price Target
$6
2026-06-04
initiated
NULL
to
Buy
Reason
Craig-Hallum initiated coverage of Sera Prognostics with a Buy rating and $6 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SERA
Unlock Now

People Also Watch